Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium sulfate + potassium sulfate + magnesium sulfate is a low-volume osmotic laxative combination used for colon cleansing in preparation for colonoscopy. The drug consists of poorly absorbed sulfate salts that create an osmotic gradient within the intestinal lumen, drawing water into the bowel to induce diarrhea and effectively evacuate fecal matter. It is typically administered as a split-dose or one-day regimen, where the concentrated solution is diluted with water and followed by additional clear liquids. Developed by Braintree Laboratories (now part of Sebela Pharmaceuticals) and licensed to partners like Ipsen and Nihon Pharmaceutical, it is approved for use in both adult and pediatric patients aged 12 years and older.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfate + potassium sulfate + magnesium sulfate.